Φορτώνει......
Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma
AIMS: Rituximab has dramatically improved the survival of patients with non-Hodgkin's lymphoma (NHL). However, studies have suggested that the dose regimen currently used (i.e. 375 mg m(−2)) could be optimized. The aims of this study were to quantify the benefits of the new dose regimen for rit...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Blackwell Science Inc
2012
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3376436/ https://ncbi.nlm.nih.gov/pubmed/21999172 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2011.04125.x |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|